Robin L. Jones
罗宾·琼斯
MD, MRCP
Professor of Sarcoma Oncology; Head, Sarcoma Unit
👥Biography 个人简介
Robin L. Jones, MD, MRCP is Professor of Sarcoma Oncology and Head of the Sarcoma Unit at the Royal Marsden Hospital and the Institute of Cancer Research (ICR) in London. He leads one of Europe's largest and most active sarcoma clinical research programs, with particular expertise in histotype-specific clinical trial design, novel systemic therapies, and translational biomarker research. His unit treats patients with a wide range of rare sarcoma subtypes and runs numerous investigator-initiated and industry-sponsored trials. Dr. Jones has been a principal investigator or co-investigator in many landmark sarcoma trials, including studies of olaratumab, trabectedin, and novel antibody-drug conjugates. He is a leading voice in global sarcoma research networks and has been instrumental in developing the EORTC Soft Tissue and Bone Sarcoma Group's clinical trials portfolio. He has authored over 250 peer-reviewed publications and is a highly sought-after collaborator in the sarcoma research community.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Olaratumab Phase II Trial and Translational Follow-Up
Served as a leading European investigator in the olaratumab (anti-PDGFRα) development program and contributed critical translational analyses to understand the biology underlying observed responses, informing the broader field's understanding of PDGFRα targeting in sarcoma.
Antibody-Drug Conjugate Development in Sarcoma
Pioneered clinical evaluation of novel ADCs including upifitamab rilsodotin (UpRi, anti-NaPi2b) and other payload-conjugated agents in specific sarcoma subtypes, establishing the Royal Marsden as a global reference center for sarcoma ADC trials.
Histotype-Stratified Clinical Trial Design
Championed the paradigm shift toward histotype-specific sarcoma trials, leading basket trials and subtype-enriched studies that have replaced the era of histology-agnostic approaches and enabled more meaningful efficacy signals in rare sarcoma subtypes.
EORTC Sarcoma Group Leadership
Played a pivotal role in the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group, coordinating multi-national clinical trials and establishing harmonized response assessment and eligibility criteria across European sarcoma centers.
Representative Works 代表性著作
Doxorubicin plus olaratumab versus doxorubicin monotherapy for treatment of soft-tissue sarcoma
The Lancet (2016)
Phase Ib/II trial demonstrating striking survival benefit with olaratumab plus doxorubicin in soft tissue sarcoma, leading to accelerated FDA/EMA approval, with subsequent phase III trial informing limits of single-arm extrapolation.
Cabozantinib in patients with advanced leiomyosarcoma
European Journal of Cancer (2023)
Phase II evaluation of cabozantinib demonstrating clinical activity in advanced leiomyosarcoma, supporting further investigation of multi-kinase inhibition in this chemotherapy-resistant subtype.
Novel systemic therapy approaches in soft tissue sarcoma: a review
Annals of Oncology (2021)
Comprehensive review of emerging systemic therapy strategies including immunotherapy, targeted agents, and ADCs in soft tissue sarcoma, outlining a framework for rational subtype-specific drug development.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 罗宾·琼斯 的研究动态
Follow Robin L. Jones's research updates
留下邮箱，当我们发布与 Robin L. Jones（Royal Marsden Hospital / Institute of Cancer Research）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment